Re-screening adherence to multi-target stool DNA test for colorectal cancer: real-world study in a large national population
International Journal of Colorectal Disease · 2025
DOI: 10.1007/s00384-025-04837-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2025. Verfasst von Mallik Greene und 8 weiteren Autor:innen. Beteiligte Einrichtung: Exact Sciences Corporation, Madison, WI, USA. magreene@exactsciences.com. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Feces, Early Detection of Cancer, Patient Compliance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Adherence to colorectal cancer (CRC) re-screening is essential to maximize screening effectiveness. This study assessed adherence to a multi-target stool DNA (mt-sDNA) test among previous users in the USA across different payer types.
Methods
Data from Exact Sciences Laboratories LLC (01/01/2023–12/31/2023) were used. Insured patients (45–85 years) who were shipped an mt-sDNA test during the data coverage period and had previously completed mt-sDNA screening with a negative result ≥ 2.5 years prior were included. Mt-sDNA re-screening adherence rate and mean time to test return were compared across payer types, and their associations with patient characteristics were assessed using multivariable regression models.
Results
Of 793,567 patients (50–75 years: 89.0%; female: 62.0%), the re-screening adherence rate was 84.0% (from 66.5% for Medicaid to 90.2% for Medicare); mean (standard deviation) time to test return was 20.7 (20.8) days (from 19.2 [19.7] for Medicare to 22.4 [22.2] for Medicaid). Characteristics associated with higher likelihood of re-screening adherence included older ages (odds ratio [OR] = 1.25 and 1.11 for 65–75 and 76–85 years, respectively, relative to 45–49 years), living in a ZIP code with higher median household income (OR = 1.80 for > $200,000 relative to < $50,000), full digital outreach (OR = 1.84 relative to no digital outreach), and ≥ 3rd rounds of screening (OR = 2.44 relative to 2nd round of screening).
Conclusion
Adherence to CRC re-screening with mt-sDNA test was high across payer types, with sustained adherence in later rounds of screening. Strategies to improve re-screening rates in subgroups associated with lower re-screening adherence are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Exact Sciences Corporation, Madison, WI, USA. magreene@exactsciences.com.
- Exact Sciences Corporation, Madison, WI, USA.
- Department of Medicine, Duke University, Durham, NC, USA.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
- Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Zitieren
APA
Greene, M., Pew, T., Dore, M., Ebner, D. W., Ozbay, A. B., Johnson, W. K., Kisiel, J. B., Fendrick, A. M., & Limburg, P. (2025). Re-screening adherence to multi-target stool DNA test for colorectal cancer: real-world study in a large national population. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-025-04837-6
Vancouver
Greene M, Pew T, Dore M, Ebner DW, Ozbay AB, Johnson WK, et al. Re-screening adherence to multi-target stool DNA test for colorectal cancer: real-world study in a large national population. International Journal of Colorectal Disease. 2025. doi:10.1007/s00384-025-04837-6
BibTeX
@article{Greene2025,
author = {Greene, Mallik and Pew, Timo and Dore, Michael and Ebner, Derek W and Ozbay, A Burak and Johnson, William K and Kisiel, John B and Fendrick, A Mark and Limburg, Paul},
title = {Re-screening adherence to multi-target stool DNA test for colorectal cancer: real-world study in a large national population},
journal = {International Journal of Colorectal Disease},
year = {2025},
doi = {10.1007/s00384-025-04837-6}
}
EUVIMED